Insider Selling: Arcus Biosciences (NYSE:RCUS) Insider Sells $110,537.76 in Stock

Arcus Biosciences, Inc. (NYSE:RCUS) insider Richard Markus sold 5,052 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $21.88, for a total value of $110,537.76. Following the completion of the transaction, the insider owned 70,141 shares of the company’s stock, valued at $1,534,685.08. The trade was a 6.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Richard Markus also recently made the following trade(s):

• On Wednesday, December 17th, Richard Markus sold 4,494 shares of Arcus Biosciences stock. The stock was sold at an average price of $22.16, for a total value of $99,587.04.

Arcus Biosciences Stock Performance

Shares of NYSE RCUS opened at $21.99 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. The stock has a 50 day moving average price of $21.10 and a 200 day moving average price of $14.16. The stock has a market capitalization of $2.37 billion, a PE ratio of -6.39 and a beta of 0.75. Arcus Biosciences, Inc. has a 52 week low of $6.50 and a 52 week high of $26.40.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.06. The company had revenue of $26.00 million for the quarter, compared to analysts’ expectations of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The business’s revenue was down 45.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.00) EPS. Analysts predict that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Key Stores Impacting Arcus Biosciences

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Arcus will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2026 — a high‑visibility forum that can accelerate investor interest, provide clinical/program updates and attract buy‑side attention ahead of catalysts. Arcus to Present at JPM
• Neutral Sentiment: Recent analyst notes are mixed-to-constructive: some firms raised price targets and UBS/Bank of America reaffirmed coverage, producing a consensus “Moderate Buy” and an elevated average target — this supports upside but depends on upcoming clinical and commercial news. MarketBeat analyst summary
• Negative Sentiment: Significant, clustered insider selling occurred Dec. 16–18: CEO Terry Rosen sold large blocks (multiple filings totaling ~54k shares across two days), and other senior officers (CFO, COO, President, CAO, General Counsel and others) also sold shares — this concentrated executive selling is likely weighing on sentiment and may prompt short‑term selling pressure. See CEO SEC filing for details. CEO Form 4
• Negative Sentiment: Additional insider sales (CAO Alexander Azoy, CFO Robert Goeltz II, COO Jennifer Jarrett, President Juan Jaen, General Counsel Carolyn Tang, and insider Richard Markus) were filed and aggregated to meaningful dollar amounts — investors often interpret broad leadership selling as a negative signal even when trades may be for diversification or tax reasons. InsiderTrades summary

Institutional Investors Weigh In On Arcus Biosciences

Several hedge funds have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Arcus Biosciences by 39.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,120,062 shares of the company’s stock worth $15,233,000 after acquiring an additional 314,757 shares during the period. Vestal Point Capital LP bought a new position in shares of Arcus Biosciences during the third quarter worth approximately $3,400,000. Public Employees Retirement System of Ohio acquired a new stake in Arcus Biosciences during the 3rd quarter worth approximately $299,000. Parkman Healthcare Partners LLC boosted its stake in Arcus Biosciences by 8.9% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 652,680 shares of the company’s stock valued at $8,876,000 after purchasing an additional 53,070 shares during the period. Finally, Decheng Capital LLC boosted its stake in Arcus Biosciences by 242.3% in the 3rd quarter. Decheng Capital LLC now owns 547,609 shares of the company’s stock valued at $7,447,000 after purchasing an additional 387,609 shares during the period. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on RCUS. Wedbush set a $35.00 price objective on shares of Arcus Biosciences and gave the company an “outperform” rating in a research report on Wednesday, October 29th. Wells Fargo & Company boosted their price target on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Monday, October 20th. UBS Group restated a “buy” rating on shares of Arcus Biosciences in a research note on Monday, December 15th. Bank of America lifted their target price on Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a research note on Friday, November 28th. Finally, Wall Street Zen raised Arcus Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, December 14th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $28.89.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.